INCREASED PLASMA-LEVELS OF SOLUBLE THROMBOMODULIN IN PATIENTS WITH SEPSIS AND ORGAN FAILURE

被引:60
作者
IBA, T
YAGI, Y
KIDOKORO, A
FUKUNAGA, M
FUKUNAGA, T
机构
[1] Department of Surgery, Juntendo Urayasu Hospital, Juntendo University School of Medicine, Chiba, 279, 2-1-1 Tomioka, Urayasu
来源
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 07期
关键词
THROMBOMODULIN; SEPSIS; ORGAN FAILURE; INTERLEUKIN-6; POLYMORPHONUCLEAR LEUKOCYTE ELASTASE;
D O I
10.1007/BF00311430
中图分类号
R61 [外科手术学];
学科分类号
摘要
The fact that thrombomodulin (TM) is released into the bloodstream from damaged vascular endothelial cells led us to hypothesize that plasma levels of soluble TM could be an indicator of the development of organ failure. In this study, we examined the changes in plasma levels of TM in 60 septic patients and 13 postsurgical patients, and investigated the circulating levels of interleukin 6(IL-6) and polymorphonuclear leukocyte elastase (PMN-E) to determine the mechanism causing the excess liberation of TM. The arterial ketone body ratio (AKBR) was also measured as an indicator of the hepatocyte energy state. Of the 60 septic patients, 26 developed organ failure, 10 of whom died. In contrast, none of the postsurgical patients developed organ failure. The mean plasma level of TM was significantly higher in the septic patients who developed organ failure compared to those without organ failure (P < 0.001) or the postsurgical patients (P < 0.001). Furthermore, those patients whose plasma TM values became elevated over 6.0 ng/ml frequently developed complications. A positive correlation was also observed between the plasma TM levels and the IL-6 (P < 0.01) and PMN-E levels (P < 0.01). In contrast, a negative correlation was seen between the plasma TM levels and the AKBR (P < 0.01). These findings show that plasma TM could be a useful indicator of impending organ failure during sepsis.
引用
收藏
页码:585 / 590
页数:6
相关论文
共 26 条
  • [1] Maruyama I., Thrombomodulin: an endothelial anticoagulant
  • [2] its structure, function and expression, Jpn Circ J, 56, pp. 187-191, (1992)
  • [3] Maruyama I., Majerus P.W., The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells, J Biol Chem, 260, pp. 15432-15438, (1985)
  • [4] Ishii H., Majerus P.W., Thrombomodulin is present in human plasma and urine, J Clin Invest, 76, pp. 2178-2181, (1985)
  • [5] Kodama S., Uchijima E., Nagai M., Mikawatani K., Hayashi T., Suzuki K., One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies, Clinica Chimica Acta, 192, pp. 191-200, (1990)
  • [6] Wada H., Ohiwa M., Kaneko T., Tamaki S., Tanigawa M., Shirakawa S., Koyama M., Hayashi T., Suzuki K., Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, Am J Hematol, 39, pp. 20-24, (1992)
  • [7] Iwashima Y., Sato T., Watanabe K., Ooshima E., Hiraishi S., Ishii H., Kazama M., Makino I., Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy, Diabetes, 39, pp. 983-988, (1990)
  • [8] Definitions for sepsis and organ failure and guidelines for the use of innovative therapeutics in sepsis, Crit Care Med, 20, pp. 864-874, (1992)
  • [9] Kodama N., Maegawa T., Takada M., Tanaka H., Gonmori H., Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan, Biol Haematol, 49, pp. 265-275, (1987)
  • [10] Hayashi T., Suzuki K., Monoclonal antibodies for human thrombomodulin which recognize binding sites for thrombin and protein C, J Biochem, 108, pp. 874-878, (1990)